Saltar al contenido
Merck

Bcl-2 is a critical mediator of intestinal transformation.

Nature communications (2016-03-10)
Maartje van der Heijden, Cheryl D Zimberlin, Anna M Nicholson, Selcuk Colak, Richard Kemp, Sybren L Meijer, Jan Paul Medema, Florian R Greten, Marnix Jansen, Douglas J Winton, Louis Vermeulen
RESUMEN

Intestinal tumour formation is generally thought to occur following mutational events in the stem cell pool. However, active NF-κB signalling additionally facilitates malignant transformation of differentiated cells. We hypothesized that genes shared between NF-κB and intestinal stem cell (ISCs) signatures might identify common pathways that are required for malignant growth. Here, we find that the NF-κB target Bcl-2, an anti-apoptotic gene, is specifically expressed in ISCs in both mice and humans. Bcl-2 is dispensable in homeostasis and, although involved in protecting ISCs from radiation-induced damage, it is non-essential in tissue regeneration. Bcl-2 is upregulated in adenomas, and its loss or inhibition impairs outgrowth of oncogenic clones, because Bcl-2 alleviates apoptotic priming in epithelial cells following Apc loss. Furthermore, Bcl-2 expression in differentiated epithelial cells renders these cells amenable to clonogenic outgrowth. Collectively, our results indicate that Bcl-2 is required for efficient intestinal transformation following Apc-loss and constitutes a potential chemoprevention target.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Bcl-2 Active human, recombinant, expressed in E. coli, ≥80% (SDS-PAGE)